A deep dive into Jubilant Pharmova (JUBLPHARMA) — examining the financials, valuation picture, and who owns the stock.
Jubilant Pharmova Revenue Trend
Revenue rose 7.7% to ₹7,291 Cr in FY2025 for Jubilant Pharmova, against ₹6,772 Cr the year before.
Stepping back, Jubilant Pharmova's 2.3% revenue CAGR over 10 years is tepid, barely outpacing inflation.
With a top line of ₹7,291 Cr, Jubilant Pharmova operates at a mid-sized scale within the pharmaceuticals sector.
Revenue has moved in the same direction for 4 years running, suggesting the growth trend has structural legs.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹7,291 Cr | +7.7% |
| FY2024 | ₹6,772 Cr | +7.1% |
| FY2023 | ₹6,320 Cr | +2.9% |
| FY2022 | ₹6,141 Cr | +0.4% |
| FY2021 | ₹6,116 Cr | — |
View Jubilant Pharmova's full 10-year revenue trend with CAGR analysis →
Jubilant Pharmova Profitability
Bottom-line growth was evident, with Jubilant Pharmova posting ₹836 Cr in net profit for FY2025 — up 1050.3% from ₹72.7 Cr.
The company squeezed out better margins in FY2025, with net margin at 11.5% versus 1.1% in FY2024.
At ₹52.85 per share (diluted), FY2025 earnings were up year-over-year from ₹4.86.
Is Jubilant Pharmova Undervalued
Under the P/E Ratio approach, Jubilant Pharmova's estimated fair value is ₹918 (6.2% downside).
Jubilant Pharmova shares are currently trading at ₹978.85.
Craytheon also calculates intrinsic value using the EPS Growth model. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹918 | 6.2% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
See all valuation models for Jubilant Pharmova with detailed assumptions →
Jubilant Pharmova Shareholding Pattern
A stable promoter holding of 47.7% over 4 quarters suggests the management group is comfortable with its position.
The FII stake is at 15.9% as of March 2026, compared to 17.4% in the year-ago period.
Domestic investors held 11.6% of the company as of March 2026, up year-over-year from 9.5%.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 47.7% | 15.9% | 11.6% | 24.2% |
| Dec 2025 | 47.7% | 16.0% | 11.2% | 24.6% |
| Sep 2025 | 47.7% | 16.6% | 10.5% | 24.6% |
| Jun 2025 | 47.7% | 17.4% | 9.5% | 24.8% |
Track quarterly shareholding changes for Jubilant Pharmova →
Jubilant Pharmova Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹127.56B (up 10.5% YoY from ₹115.49B).
Top categories: Property, Plant & Equipment (38.0%), Intangibles & Goodwill (28.5%), Inventories (8.9%).
Of the ₹127.56B in liabilities and equity, 48.9% is shareholder equity, 19.1% is interest-bearing debt, and 32.0% is operating liabilities. Over the year, debt is down 28.6% and equity is up 15.1%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 10.89B |
| Receivables | 8.92B |
| Inventories | 11.29B |
| Property, Plant & Equipment | 48.47B |
| Investments | 435.00M |
| Intangibles & Goodwill | 36.38B |
| Other Assets | 11.19B |
| Category | Value |
|---|---|
| Equity | 62.39B |
| Short-term Debt | 2.87B |
| Long-term Debt | 21.50B |
| Trade Payables | 15.79B |
| Other Liabilities | 25.02B |
Jubilant Pharmova at a Glance
Bringing the key threads together for Jubilant Pharmova (JUBLPHARMA) as a pharmaceuticals investment opportunity.
Revenue of ₹7,291 Cr in FY2025, up 7.7% year-over-year.
Long-term revenue has been compounding at 2.3% annually over 10 years.
The company is profitable, with a net margin of 11.5% and net income of ₹836 Cr.
The P/E Ratio model implies 6.2% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Jubilant Pharmova.